Product Safety: The investigational product is an oral nutritional sachet consisting of organic Class A Canadian maple and Himalayan salt. Based on its composition, route of administration, and intended oral use, the anticipated safety risks of the investigational product are expected to be low in appropriately screened participants when consumed at the protocol-specified dose. The product is composed of commonly consumed food-derived ingredients and does not contain a synthetic pharmacologic active ingredient, stimulant, controlled substance, alcohol, or ingredient with known abuse or dependence potential. No central nervous system, respiratory, or direct cardiovascular pharmacology is anticipated beyond effects that may occur indirectly through carbohydrate intake, sodium exposure, fluid balance, hydration status, or individual dietary context.

The principal foreseeable safety consideration for this formulation is its carbohydrate and sugar content. Each sachet contains 40 g of carbohydrates, including 39 g of sugars. Participants with diabetes, impaired glucose regulation, clinically significant insulin resistance, hypoglycemia risk, or any condition requiring strict dietary carbohydrate control may be at increased risk of transient elevations or fluctuations in blood glucose. These individuals should be excluded unless the protocol specifically allows their participation with appropriate monitoring. Depending on the study population, monitoring may include baseline medical history, concomitant medication review, fasting or post-prandial glucose assessment, hemoglobin A1c, or participant-reported symptoms of hyperglycemia or hypoglycemia.

The product also contains 0.5 g salt and 200 mg sodium per sachet. Although this sodium exposure is modest in the context of ordinary dietary intake, it may be clinically relevant for participants with sodium-restricted diets, uncontrolled hypertension, heart failure, clinically significant cardiovascular disease, renal impairment, edema, or disorders of fluid or electrolyte balance. Such participants should be excluded or monitored according to the protocol. Safety monitoring may include blood pressure, renal function, serum electrolytes, weight, edema symptoms, and concomitant medication review, particularly for participants using diuretics, antihypertensives, glucose-lowering medications, or other therapies that may affect fluid, electrolyte, or glucose balance.

The mineral content of the product is expected to be low to moderate at the proposed serving size. However, because the product contains potassium, magnesium, manganese, copper, zinc, calcium, and sodium, participants with clinically significant renal disease, hepatic disease, known mineral metabolism disorders, or medically prescribed restrictions on mineral intake should be excluded or evaluated carefully before enrollment. If the study involves repeated daily use over an extended period, the protocol should specify whether laboratory monitoring of electrolytes, renal function, or hepatic function is required based on the risk profile of the enrolled population.

Potential adverse events may include nausea, abdominal discomfort, bloating, diarrhea, constipation, reflux, headache, thirst, increased urination, transient changes in energy, transient changes in blood glucose, or symptoms related to sodium or fluid balance. Less commonly, participants may experience intolerance or hypersensitivity-type reactions, including rash, itching, swelling, wheezing, or difficulty breathing. Participants should be instructed to discontinue the investigational product and seek medical attention for symptoms suggestive of serious allergic reaction, severe gastrointestinal symptoms, chest pain, shortness of breath, syncope, severe headache, confusion, clinically significant swelling, or any other medically concerning event.

The proposed study will minimize risk through eligibility criteria, dose control, participant instructions, and adverse event monitoring. Participants should be instructed to consume no more than the protocol-specified amount, to avoid substituting the product for medically necessary nutrition, hydration, or prescribed therapy, and to report adverse symptoms promptly. The protocol should collect baseline medical history, relevant dietary restrictions, concomitant medications and supplements, and adverse events throughout the study period. Adverse events should be assessed for seriousness, severity, expectedness, and relatedness to the investigational product.

No product-specific nonclinical toxicology studies are included in this draft safety summary. Given that the investigational product is composed of commonly consumed food-derived ingredients and is proposed for oral administration at a limited daily dose, existing human dietary exposure to the ingredient class may support initial clinical evaluation in an appropriately selected population. This conclusion is contingent on adequate chemistry, manufacturing, and controls information, including ingredient identity, batch consistency, microbiological quality, heavy metal limits, contaminant testing, sodium and mineral specifications, packaging compatibility, and stability data sufficient to support the planned clinical exposure period.

The chemistry, manufacturing, and controls program should ensure that the investigational product is consistently manufactured, labeled, packaged, stored, and distributed in a manner that preserves product identity, quality, purity, strength, and stability throughout the clinical investigation. Because maple-derived products and mineral salts may vary by source and lot, certificates of analysis should be maintained for each clinical lot, and specifications should be established for identity, composition, microbiological quality, heavy metals, adulterants, and other relevant contaminants.

Based on the available information, the anticipated safety profile of the investigational product is acceptable for evaluation in a limited clinical study of appropriately screened participants, provided that the protocol includes dose control, exclusion or monitoring of participants at increased risk from sugar, sodium, mineral, renal, cardiovascular, hepatic, or metabolic considerations, clear stopping rules, and prompt review and reporting of adverse events.

Product Safety: